

**Report on Proposed Commissioning Intentions for: Administration of GnRH Analogues**

**Date of Report: 20 March 2018**

**Report Author: Rachel Singyard – Service Manager**

## **Background**

Following agreement at the January 2018 Joint Co-Commissioning Committee to continue commissioning a number of PMS reinvestment schemes from general practice, this report has been prepared to provide additional background information regarding the rationale for the future commissioning intentions for the Administration of GnRH Analogues.

This service has been commissioned since 2015, and is funded through the PMS premium monies.

The Committee members should note that in these cases where there has been agreement to continue to commission services for a further 3 year term, this does not preclude any future decisions and actions that may be required to vary or even terminate the contract should the requirements evolve and/or circumstances change, as long as these are enacted in line with contractual clauses.

## **Service Description**

The service is intended to provide the administration of Gonadorelins (Prostap mainly) which are used in the treatment of carcinoma of the prostate. It is also intended to monitor patients who have a borderline PSA level (an indicator of potential prostate problem). The administration of GnRH analogues service follows on from secondary treatment and encompasses 2 levels as outlined below:

- **Level 1**  
Borderline PSA – on-going monitoring
- **Level 2**  
Stable patient with Carcinoma of Prostate post radiotherapy;  
Stable patient with Carcinoma of the Prostate requiring ongoing hormone manipulation.

If the service was not provided by their practice patients would be seen within the hospital and therefore the service is aimed at secondary care avoidance and improved convenience for patients.

## **Scope of delivery of service**

The service is delivered by all NEL Practices.

## Funding

The service is funded on an annual payment per patient which is as follows:

Service Description	Currency	Price
Administration of GnRH Analogues	Level 1	<b>£80.33</b>
	Level 2	<b>£160.65</b>

The forecast outturn for 2017/18 is £165,065.

Benchmarking against other local CCGs shows that NELCCG reimburses a higher amount for this service, although not all of these are directly comparable as some CCGs pay per visit and some pay per annum per patient; other local CCGs are paying approximately £45 per patient per annum. It should be noted that an outpatient follow up attendance in a hospital Urology clinic would cost £55.35 and patients are seen as a minimum every 6 months. The Level 2 service would incur a procedure charge instead of the outpatient cost which would be £66.25, and patients could have on average between 2 and 4 attendances per year.

## Monitoring and assurance

The service is monitored through an annual audit submitted and reviewed by the CCG.

## Implications of not having service in place

If the CCG did not continue to commission this service from general practice, the impact would be an increase in hospital outpatient attendances and inconvenience for patients in having to attend hospital appointments. However, capacity would be a significant issue, as the Urology service at the hospital has high demand and capacity issues.

## Proposed commissioning recommendation

It is proposed that this service is continued to be commissioned with a review of the pathway to reflect latest guidance, if applicable. The payment will also be reviewed to ensure VFM.